AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18676330
Drug: Temsirolimus, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus, administered at a flat weekly IV dose of 25 mg over 30-60 minutes
Trial: 18676330
Drug: Interferon-alpha (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (standard therapy)
Trial: 12505817
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of E-EPA
Trial: 8801700
Drug: Low S-citalopram
RxNorm normalized name: S-(+)-Citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low S-citalopram due to carbamazepine treatment
Trial: 6377873
Drug: Cranial radiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial radiation therapy
Trial: 6377873
Drug: No cranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cranial radiation therapy (Control)
Trial: 25603750
Drug: Low‐Level Laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐Level Laser Therapy (LLLT)
Trial: 30559886
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MOPs and LLLT
Trial: 25013370
Drug: Benidipine (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine (4.8 mg/day)
Trial: 25013370
Drug: Hydrochlorothiazide (8.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (8.2 mg/day)
Trial: 22665131
Drug: Beeswax and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beeswax and herbal oil cream
Trial: 19483369
Drug: Stress Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress Management Training (SMT) program with monthly 30-min sessions for 6 months
Trial: 18260374
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of pulmicort 2 ml plus 0.5% Aeuromycin solution 10 ml by oxygen driving force, once a day for 3 weeks
Trial: 7587848
Drug: Alprazolam (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (up to 2 mg/day)
Trial: 2245970
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy, dosage: around 2 IU/m2/day, duration: 12 months
Trial: 2245970
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration to normal subjects
Trial: 29363217
Drug: Clobazam 20
RxNorm normalized name: cloBAZam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam 20 mg
Trial: 27635023
Drug: Radiopeptide therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopeptide therapy (90Y‐DOTATOC or 177Lu‐DOTATOC)
Trial: 26473561
Drug: Resilience training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resilience training combined with cognitive behavioral and solution-focused counseling
Trial: 24220602
Drug: Automated software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated software system for identifying patients eligible for OAC therapy and increasing uptake, used in 23 intervention practices for 6 months.
Trial: 24220602
Drug: Automated software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated software system for identifying patients eligible for OAC therapy.
Trial: 19742335
Drug: Resection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resection of pancreatic capsule and anterior layer of transverse mesocolon (Group R)
Trial: 17719390
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of autologous platelet-poor plasma (PPP) gel
Trial: 15121561
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined estrogen plus progestin therapy (2 mg of 17 beta‐estradiol plus 1 mg of norethisterone acetate)
Trial: 15121561
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined estrogen plus progestin therapy
Trial: 11346146
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b 3 Million Units thrice weekly (group A)
Trial: 11346146
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b 5 Million Units thrice weekly (group B)
Trial: 11346146
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b 5 Million Units daily (group C)
Trial: 9876054
Drug: Amoxycillin/clavulanate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate (250 mg/62 mg t.i.d. or 125 mg/31 mg t.i.d. if aged under 6 years) for 7 days
Trial: 9876054
Drug: Cefaclor (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (250 mg t.i.d. or 125 mg t.i.d. if aged under 6 years) for 7 days
Trial: 2491982
Drug: Adjusted probabilities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted probabilities of discontinuation for ICD
Trial: 2491982
Drug: Adjusted probabilities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted probabilities of discontinuation for LNG‐IUD
Trial: 2491982
Drug: Adjusted probabilities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted probabilities of discontinuation for Nova‐T
Trial: 31760109
Drug: Integrated psychosocial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated psychosocial treatment (Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention)
Trial: 31760109
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care through a Veteran's Administration co‐occurring disorders medical clinic
Trial: 27908210
Drug: Combined hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormonal contraceptive (COC) containing 0.020 mg of ethynyl estradiol (EE)
Trial: 27908210
Drug: Combined hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormonal contraceptive (COC) containing 0.030 mg of ethynyl estradiol (EE)
Trial: 27908210
Drug: Natural COC
RxNorm normalized name: GLYCERIN 6 g in 100 mL TOPICAL SOLUTION [Natural Cocktail Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural COC containing 1.5 mg of estradiol (E2)
Trial: 27908210
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring releasing 0.015 mg of EE + 0.120 mg of etonogestrel
Trial: 27908210
Drug: Progestin only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin only subcutaneous contraceptive implant releasing etonogestrel
Trial: 25425394
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300U/ml (Gla‐300) administered at a dosage of 0.4U/kg once daily for six days
Trial: 25425394
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300U/ml (Gla‐300)
Trial: 23778372
Drug: Usual chiropractic
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual chiropractic treatment
Trial: 19261771
Drug: wP vaccine
RxNorm normalized name: WP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wP vaccine
Trial: 19261771
Drug: wP(low) vaccine
RxNorm normalized name: WP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wP(low) vaccine
Trial: 16954234
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with both GBV-C E2 antibody and viremia
Trial: 11332870
Drug: Piracetam treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam treatment
Trial: 30290629
Drug: Gel cushion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel cushion
Trial: 23871316
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and maxillofacial surgeon
Trial: 22002111
Drug: Intraprostatic injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic injection of epinephrine
Trial: 22002111
Drug: Intraprostatic injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraprostatic injection of saline solution (placebo)
Trial: 18261506
Drug: Paroxetine controlled‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine controlled‐release (12.5‐25 mg/d)
Trial: 11575418
Drug: Inhaled isoflurane
RxNorm normalized name: isoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoflurane at end‐tidal concentration 1‐1.5% (group I, n=20)
Trial: 11575418
Drug: Target‐controlled infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target‐controlled infusion (TCI) of propofol at target concentration 2‐5 microg ml(‐1) (group P, n=18)
Trial: 9932224
Drug: Biological tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological tests before clinical symptoms
Trial: 8060926
Drug: Candoxatril 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 200 mg twice daily for 4 weeks
Trial: 26246480
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral steroid administration
Trial: 26246480
Drug: Endoscopic local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic local steroid injection
Trial: 23831870
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rifampin (600 mg)
Trial: 19401528
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (13‐cis RA and 13‐cis RA/alpha tocopherol)
Trial: 12577389
Drug: Compound Aspirin
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Aspirin (APC)
Trial: 9359049
Drug: High-dose dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dipyridamole (up to 0.84 mg/kg over 10')
Trial: 9359049
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine (up to 10 mcg/kg/min)
Trial: 8000787
Drug: Leptospirosis vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptospirosis vaccine
Trial: 23240711
Drug: Alcohol infusion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol infusion (target breath alcohol concentration = 0.06 g/dl)
Trial: 28675116
Drug: Alcohol infusion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol infusion
Trial: 22022215
Drug: Ethyl chloride
RxNorm normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride vapocoolant spray
Trial: 19691847
Drug: Temporary fracture
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary fracture fixation with fixateur externe and defined secondary definitive treatment (DCO)
Trial: 15614996
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phase synchronization measures with alpha power spectral density estimates
Trial: 8068482
Drug: Intramuscular recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular recombinant IFN alpha‐2b
Trial: 3711577
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1% tropicamide and 2.5% phenylephrine
Trial: 21865014
Drug: Active Treatment
RxNorm normalized name: Active
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Treatment (AT)
Trial: 22235841
Drug: Formoterol 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 9 μg via Turbuhaler®
Trial: 22235841
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 μg via Diskus®
Trial: 18827613
Drug: Dose-dense docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim without BNP7787 (Group A)
Trial: 18827613
Drug: Dose-dense docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense docetaxel and cisplatin with darbepoetin and pegfilgrastim with BNP7787 (Group B)
Trial: 16408240
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airways pressure therapy (CPAP)
Trial: 10798794
Drug: Loprazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loprazolam (2 mg)
Trial: 9275691
Drug: Osmosis chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmosis chemotherapy (5-FU)
Trial: 26762482
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% rebamipide
Trial: 26762482
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment with rebamipide)
Trial: 24583430
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (5-15 mg/day of prednisolone and 6 mg/week of methotrexate)
Trial: 21059430
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level <120 g/L
Trial: 21059430
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level 120 to 139 g/L
Trial: 21059430
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level 140 to 159 g/L
Trial: 21059430
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level >160 g/L
Trial: 10599988
Drug: [1‐(13)C]KIC infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [1‐(13)C]KIC infusion
Trial: 10599988
Drug: [5,5,5‐2H3]KIC infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [5,5,5‐2H3]KIC infusion
Trial: 1663282
Drug: 4-drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug combination of 7-10 mg/kg rifabutin, 5 mg/kg isoniazid, 20 mg/kg ethambutol and 100 mg clofazimine
Trial: 6136959
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose isosorbide dinitrate in combination with nadolol
Trial: 6136959
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose nifedipine in combination with nadolol
Trial: 6136959
Drug: Nadolol alone
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol alone and in combination with isosorbide dinitrate or nifedipine
Trial: 6136959
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose nifedipine
Trial: 6136959
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate in combination with nadolol
Trial: 6136959
Drug: Isosorbide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide treatment periods
Trial: 28674765
Drug: TAC (triplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (triplet chemotherapy)
Trial: 22744970
Drug: α(1)‐adrenoreceptor blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α(1)‐adrenoreceptor blockade with prazosin (0.05 mg/kg)
Trial: 15061656
Drug: Standard micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard micronutrient supplementation in patients under long term parenteral nutrition
Trial: 11785713
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of ranitidine bismuth citrate 400 mg bid, clarithromycin 500 mg bid, and tinidazole 500 mg bid
Trial: 11785713
Drug: 10-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day course of omeprazole 20 mg bid plus amoxycillin 1 g bid for the first 5 days, and omeprazole 20 mg bid, clarithromycin 500 mg bid and tinidazole 500 mg bid for the remaining 5 days
Trial: 9408064
Drug: Cyclical oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical oral clodronate with calcium supplementation
Trial: 3896664
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg pirazolac in the morning and 600 mg at night
Trial: 3896664
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg pirazolac given morning and evening
Trial: 29143534
Drug: Quetiapine-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine-based treatment
Trial: 23867841
Drug: Ramipril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (10 mg daily for 6 months)
Trial: 22779096
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% lotion
Trial: 18330677
Drug: Adalimumab 20
RxNorm normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 20 mg
Trial: 18831744
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg
Trial: 8831326
Drug: Smaller doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller doses of each drug
Trial: 8831326
Drug: Larger doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger doses of each drug
Trial: 31907860
Drug: Tailored triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored triple therapy (TATT)
Trial: 31907860
Drug: Traditional bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional bismuth-containing quadruple therapy (TRBQT)
Trial: 31907860
Drug: Tailored bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored bismuth-containing quadruple therapy (TABQT)
Trial: 28946832
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy plus medical management
Trial: 26508752
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis only
Trial: 23570501
Drug: E-CMF (epirubicin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-CMF (epirubicin-containing chemotherapy)
Trial: 17133300
Drug: Oral yohimbine
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral yohimbine
Trial: 12733777
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances
Trial: 10325911
Drug: Beta agonist
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta agonist reduction group (terbutaline dose reduced from 2500 to 500 micrograms/day)
Trial: 10325911
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (terbutaline dose reduced from 3000 to 2250 micrograms/day)
Trial: 7573829
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with depot grass pollen extract (Phleum pratense, Alutard SQ)
Trial: 7573829
Drug: Continued injection
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued injection treatment (immunotherapy)
Trial: 2109658
Drug: L-deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-deprenyl (10 mg/day)
Trial: 6110955
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin and chlorambucil